What's Happening?
A study published in the Annals of Internal Medicine in 1992 and a 2017 systematic review in JAMA Internal Medicine reveal that physicians frequently overestimate the benefits of medical treatments, particularly when presented with relative risk reductions
rather than absolute numbers. The research indicates that doctors rated treatments as less effective when shown absolute numbers or 'number needed to treat' (NNT) compared to relative risk reductions. This cognitive bias affects how physicians communicate with patients, potentially leading to inflated estimates of benefit during shared decision-making. For instance, a drug reducing heart attack risk by 50% (relative risk) sounds more impressive than lowering a five-year risk from 2% to 1% (absolute risk), despite being the same outcome. This discrepancy can influence patient consent and their understanding of treatment efficacy, as highlighted by the example of statins, where the absolute benefit is often much smaller than perceived.
Why It's Important?
This issue is critical for patient autonomy and informed consent in the U.S. healthcare system. When physicians, even unintentionally, inflate the perceived benefits of a drug, patients may make decisions based on incomplete or skewed information. This can lead to unnecessary financial burdens, exposure to side effects, and a misallocation of healthcare resources. The article points out that a public health benefit, such as preventing 10,000 events across a million people, does not negate the obligation to explain the modest individual benefit to each patient. Furthermore, the influence of industry payments, even small ones like sponsored meals, has been linked to increased prescribing of promoted brand-name drugs, raising concerns about potential conflicts of interest and their impact on prescribing patterns and patient care. This dynamic underscores the need for greater transparency and a more rigorous approach to communicating drug efficacy.
Beyond the Headlines
The deeper implication of this phenomenon extends to the ethical foundations of medical practice and the broader pharmaceutical landscape. The reliance on relative risk in marketing and medical education can create a culture where statistical significance is prioritized over clinical meaningfulness. This can lead to the widespread adoption of treatments with marginal individual benefits but high costs, impacting healthcare affordability and access. The article challenges the notion of a 'breakthrough' drug, suggesting that true breakthroughs should substantially alter the natural history of a disease, not just produce a 'slightly prettier Kaplan-Meier curve.' It also raises questions about the definition of 'effective' in medicine, arguing that without quantifying 'how much,' the term becomes nearly meaningless. This calls for a re-evaluation of how medical research is presented and how physicians are trained to interpret and communicate treatment outcomes.













